Skip to main content
. 2022 Nov 6;12(11):2714. doi: 10.3390/diagnostics12112714

Figure 1.

Figure 1

Design of the prospective cohort study.*“Very high” risk means presence of existing chronic heart failure or dilated cardiomyopathy, according to the current position papers on CTRCD [17,23,24,25]; “high” risk includes previous severe valvular heart disease, past myocardial infarction and/or revascularization, baseline left ventricular ejection fraction <50%, stable angina, or prior treatment with anthracyclines or radiation therapy (see Section 2.1.7). * Cardiac protectors: ACE inhibitors/ARBs; beta-blockers; statins; trimetazidine/analogues; others (see Section 2.1.5).